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Socio-demographic variation in stage at diagnosis of breast,
bladder, colon, endometrial, lung, melanoma, prostate, rectal,
renal and ovarian cancer in England and its population impact
M. E. Barclay1,2, G. A. Abel3, David. C. Greenberg4, B. Rous4 and G. Lyratzopoulos 1,2,4
BACKGROUND: Stage at diagnosis strongly predicts cancer survival and understanding related inequalities could guide
interventions.
METHODS: We analysed incident cases diagnosed with 10 solid tumours included in the UK government target of 75% of patients
diagnosed in TNM stage I/II by 2028. We examined socio-demographic differences in diagnosis at stage III/IV vs. I/II. Multiple
imputation was used for missing stage at diagnosis (9% of tumours).
RESULTS: Of the 202,001 cases, 57% were diagnosed in stage I/II (an absolute 18% ‘gap’ from the 75% target). The likelihood of
diagnosis at stage III/IV increased in older age, though variably by cancer site, being strongest for prostate and endometrial
cancer. Increasing level of deprivation was associated with advanced stage at diagnosis for all sites except lung and renal
cancer. There were, inconsistent in direction, sex inequalities for four cancers. Eliminating socio-demographic inequalities
would translate to 61% of patients with the 10 studied cancers being diagnosed at stage I/II, reducing the gap from target
to 14%.
CONCLUSIONS: Potential elimination of socio-demographic inequalities in stage at diagnosis would make a substantial, though
partial, contribution to achieving stage shift targets. Earlier diagnosis strategies should additionally focus on the whole
population and not only the high-risk socio-demographic groups.
British Journal of Cancer (2021) 124:1320–1329; https://doi.org/10.1038/s41416-021-01279-z
BACKGROUND
Diagnosing patients at non-advanced stage is becoming a
mainstay of contemporary cancer prevention and control
strategies, complementing cancer prevention and screening.1–4
Most cancer patients are diagnosed after symptom onset, as
effective screening tests only exist for few cancer sites and
participation in screening programmes is suboptimal.5 Therefore,
additional to efforts to optimise participation in screening, public
health policies in many countries focus on shortening intervals
from symptom onset to diagnosis to achieve population-level
reductions in advanced stage cancer.
In 2018, the UK Government has set out a target for 75% of
cancer patients with common solid tumours to be diagnosed in
tumour, node, metastasis (TNM) stage I or II by 2028.6 However,
how improvements in stage distribution could be achieved within
a decade remains uncertain. An appealing strategy to help
improve the stage distribution of incident cases is the reduction of
stage inequalities by socio-demographic groups.
Several demographic and psychosocial factors are associated
with the length of time from symptom onset to presentation
(i.e. the ‘patient interval’7), and related markers (such as
awareness of cancer symptoms or reported psychological or
practical barriers to presentation).8,9 Specifically, older and
lower socioeconomic status individuals tend to have lower
awareness of likely cancer symptoms, higher degree of practical
or emotional barriers to presentation and help-seeking and to
experience longer intervals to diagnosis.8,9 Socio-demographic
differences in stage at diagnosis are therefore likely even in
populations served by healthcare systems without financial
barriers to accessing care, though such associations may vary
between different cancer sites.
Studies from various countries have documented socio-
demographic variation in stage at diagnosis but chiefly focussed
on the most common, ‘screenable’ cancers.10–14 Previous
UK studies also tended to focus on regional, sub-national,
populations and earlier eras.15–18 Motivated by the above
considerations, we aimed to examine stage at diagnosis for
common cancers in England and related socio-demographic
variation in a recent study period with highly complete
information on stage at diagnosis. We focussed on the cancer
sites that have been used in public reporting of stage at
diagnosis in local areas in England and that relate to the current
UK government target for improving diagnosis of cancer at an
earlier stage by 2028.6
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METHODS
Data
Data were analysed on incident cases aged 30–99 years diagnosed
in 2015 with colon [International Classification of Diseases, Tenth
Revision: C18], rectal [C19–C20], lung [C33–C34], melanoma [C43],
(female) breast [C50], uterine [C54], ovarian [C56], prostate [C61],
renal [C64], and bladder [C67] cancer registered in the English
population-based cancer registry run by the Public Health England
National Cancer Registration and Analysis Service. Beyond cancer
site and integrated tumour TNM stage at diagnosis, the main
analysis used information on the following variables: age (years),
sex, small area deprivation group (fifth of the income domain of
the Index of Multiple Deprivation 2015 score of the Lower Layer
Super Output Area of the patient’s residence), screening detection
status (for breast, colon, and rectal cancers only), and morphology
group. Additional (auxiliary) variables were used in the imputation
model as described below.
Analysis
Parameterisation of stage at diagnosis. Consistent with existing
reporting conventions in England and prior literature,17–19 in the
main analysis we categorised stage at diagnosis as advanced/non-
advanced using TNM stage III/IV and I/II, respectively. We explored
alternative parameterisations in sensitivity analysis (see below).
Imputation of missing stage. Information on stage at diagnosis
was 91% complete overall (range: 85% for ovarian to 94% for
endometrial cancer). In our analysis, stage was the outcome
variable; unlike the case for exposure variables, imputation of
outcome variables is generally considered of limited value.20
However, if auxiliary variables are available, multiple imputation
reduces bias and increases power compared with complete case
analysis.21 Therefore, in the main analysis, we completed
information on stage at diagnosis using multiple imputation by
chained equations, separately for each cancer site. The imputation
models included all variables used in main analysis (i.e. age, sex,
deprivation group, screening detection status and morphology,
parameterised as in main analysis) and several auxiliary variables,
including survival (see Supplementary Information—Text Box).
Ten imputations were produced for each site.
Statistical analysis. Initially, we described the number of patients
in the data set by socio-demographic characteristic and cancer
site and compared the observed and imputed proportions
diagnosed at advanced stage by each variable.
We subsequently used three different logistic regression models
with robust standard errors, with advanced/non-advanced stage
categories being the binary outcome variable. First (Model 1) we
described variation in advanced stage across the analysis sample
(all ten studied cancer sites) adjusting for age at diagnosis (in
years; modelled using a restricted cubic spline with knots at 40, 45,
55, 65, 75 and 85 years), sex, deprivation group and cancer site.
As associations between socio-demographic variables and stage
at diagnosis could vary by cancer site, in a second model stratified
by cancer site (Model 2) we described socio-demographic
differences in stage at diagnosis (by age, sex and deprivation
group) for each studied site separately.
For patients with breast, colon and rectal cancers, to acquire
insights into the variation in stage at diagnosis that is mediated by
socio-demographic differences in the proportion of screen-
detected cases, we extended the stratified model also including
screening detection status (Model 3).
For five of the ten studied cancers (lung, breast, renal,
endometrial, ovarian), there is substantial morphological hetero-
geneity, and so all models were also adjusted for morphology
group for these sites.
In sensitivity analysis, we examined alternative parameterisa-
tions of stage i.e. advanced stage defined as TNM II–IV or IV (in
addition to III/IV in main analysis), restricting the analysis to those
with recorded stage.
Estimating population-level impact. We estimated the population
impact that would result from elimination of differences in stage
at diagnosis by age (among patients aged ≥65 years), sex (for
cancer other than female breast, prostate, ovarian and endome-
trial) and deprivation group. Specifically, we predicted the number
of cases of advanced stage cancer we would expect if:
● Everyone aged >65 years had the same risk of advanced stage
at diagnosis as those aged 65 years if the latter was lower.
● Men were to attain the same risk of advanced stage as
women, or vice versa, as applicable for the sex with the
lower risk.
● More deprived groups had the same risk of advanced stage at
diagnosis as the least deprived group, if these groups had
higher risk of advanced-stage cancer
● All above three socio-demographic differences were removed.
We applied the mi predictnl command in Stata to estimate the
difference between the modelled probability of diagnosis at
advanced stage and the probability of diagnosis at advanced stage
under the counterfactual assumptions for each individual patient.
We then summed these probabilities to estimate the total number
of advanced stage diagnoses associated with each inequality.
RESULTS
Of the 202,001 incident tumours for the studied cancers
diagnosed in 2015, 53% were diagnosed at stage I/II (‘non-
advanced stage’), 38% at stage III/IV (‘advanced stage’), and 9%
had missing stage (Table 1). After multiple imputation, 57.2 and
42.8% of tumours were diagnosed in non-advanced/advanced
stage, respectively.
Associations with advanced stage considering all the studied
cancer sites together (Model 1)
In the unadjusted analysis, there was notable variation in
advanced stage at diagnosis by sex (50 vs. 36% in men/women),
age (27 vs. 59% in those aged 30–39/90–99 years) and deprivation
group (39 vs. 49% in most/least deprived group patients). For
lung, breast, ovarian, endometrial and bladder cancer, there were
also substantial differences in stage at diagnosis by morphology
type (Table 1). There was also large variation in the percentage of
patients diagnosed at advanced stage by cancer site, ranging from
lung (74%) and ovarian cancer (72%) to breast cancer (16%) and
melanoma (9%).
In the adjusted analysis, there was large variation in advanced
stage at diagnosis in older age, with the odds increasing
exponentially from 70 years upwards (Fig. 1). However, differences
by sex and deprivation were relatively small. There was also very
large variation by cancer site, which was substantially greater than
that by age. For example, there was a 25-fold difference in the
odds of advanced stage disease between lung cancer and
melanoma (1/0.04), compared with up to 2-fold difference
between those aged 95 and 65 years (1.88/1).
Cancer site-specific adjusted associations with advanced stage at
diagnosis (Model 2)
Age and stage. Age was strongly associated with risk of advanced
stage disease for most cancer sites (p < 0.001, Fig. 2), with a
monotonic increase in the odds of advanced stage at diagnosis with
increasing age for 5 sites (melanoma, ovarian, prostate, renal and
endometrial cancer), and a U-shaped association (both the younger
and the older patients having relatively high odds of advanced
stage) for the other 5 sites (breast, lung, colon, rectal, bladder
cancer). For patients with breast, colon or rectal cancer, adjusting for
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Table 1. Univariate observed and imputed stage distribution by variable category.
Tumours Observed Imputed over 10 imputations)
Non-advanced stage Advanced stage Missing stage % non-advanced % advanced % missing % non-advanced % advanced
Total 202,001 107,409 75,997 18,595 53.2% 37.6% 9.2% 57.2% 42.8%
Cancer
Colon 23,452 9418 11,529 2505 40.2% 49.2% 10.7% 43.3% 56.7%
Rectal 11,279 4440 5884 955 39.4% 52.2% 8.5% 42.1% 57.9%
Lung 38,086 9203 25,841 3042 24.2% 67.8% 8.0% 25.8% 74.2%
Small cell 3807 210 3451 146 5.5% 90.6% 3.8% 5.7% 94.3%
Adenocarcinoma 11,946 3417 8138 391 28.6% 68.1% 3.3% 29.6% 70.4%
Squamous cell 7064 2113 4716 235 29.9% 66.8% 3.3% 30.5% 69.5%
Other non-small cell 3176 642 2429 105 20.2% 76.5% 3.3% 20.7% 79.3%
Specified other 844 424 285 135 50.2% 33.8% 16.0% 59.1% 40.9%
Unspecified 11,249 2397 6822 2030 21.3% 60.6% 18.0% 24.4% 75.6%
Melanoma 12,970 10,970 1080 920 84.6% 8.3% 7.1% 90.6% 9.4%
Breasta 45,432 35,861 6268 3303 78.9% 13.8% 7.3% 84.2% 15.8%
Infiltrating ductal carcinoma 35,116 28,703 4414 1999 81.7% 12.6% 5.7% 86.4% 13.6%
Lobular carcinoma 6036 4449 1167 420 73.7% 19.3% 7.0% 78.8% 21.2%
Mixed ductal lobular 921 719 162 40 78.1% 17.6% 4.3% 81.3% 18.7%
Other adenocarcinoma 2098 1634 260 204 77.9% 12.4% 9.7% 86.0% 14.0%
Other unspecified 1079 309 247 523 28.6% 22.9% 48.5% 43.5% 56.5%
Endometriala 7316 5556 1334 426 75.9% 18.2% 5.8% 78.8% 21.2%
Adeno/endometrial low grade 4647 4118 373 156 88.6% 8.0% 3.4% 91.2% 8.8%
Adeno/endometrial high grade 1067 619 343 105 58.0% 32.1% 9.8% 61.1% 38.9%
Serous papillary 700 349 317 34 49.9% 45.3% 4.9% 51.8% 48.2%
Carcinosarcoma 370 202 153 15 54.6% 41.4% 4.1% 55.7% 44.3%
Clear cell 232 150 70 12 64.7% 30.2% 5.2% 66.9% 33.1%
Ovariana 5002 1256 2996 750 25.1% 59.9% 15.0% 28.0% 72.0%
Serous high grade 2507 327 1921 259 13.0% 76.6% 10.3% 14.8% 85.2%
Carcinoma high grade 767 66 545 156 8.6% 71.1% 20.3% 9.7% 90.3%
Mucinous 268 217 34 17 81.0% 12.7% 6.3% 85.6% 14.4%
Unspecified/other 576 111 193 272 19.3% 33.5% 47.2% 29.0% 71.0%
Prostate 40,959 20,674 15,943 4342 50.5% 38.9% 10.6% 54.7% 45.3%
Renal 8933 4466 3297 1170 50.0% 36.9% 13.1% 56.8% 43.2%
Clear cell and papillary carcinoma 4623 2532 1736 355 54.8% 37.6% 7.7% 59.5% 40.5%
Renal cell carcinoma 3103 1458 1202 443 47.0% 38.7% 14.3% 54.2% 45.8%
Other and unspecified carcinoma 1207 476 359 372 39.4% 29.7% 30.8% 53.6% 46.4%
Bladder 8572 5565 1825 1182 64.9% 21.3% 13.8% 71.5% 28.5%
Adeno/SCC 385 152 184 49 39.5% 47.8% 12.7% 45.8% 54.2%
Non-papillary TCC 5060 3515 1082 463 69.5% 21.4% 9.2% 75.9% 24.1%
Papillary TCC 2153 1797 253 103 83.5% 11.8% 4.8% 87.3% 12.7%
Unspecified/other 974 101 306 567 10.4% 31.4% 58.2% 24.4% 75.6%
Sex
Men 98,981 45,570 43,819 9592 46.0% 44.3% 9.7% 49.8% 50.2%
Women 103,020 61,839 32,178 9003 60.0% 31.2% 8.7% 64.2% 35.8%
Age, years
30–39 3608 2474 875 259 68.6% 24.3% 7.2% 73.4% 26.6%
40–49 12,565 8638 3172 755 68.7% 25.2% 6.0% 72.8% 27.2%
50–59 28,358 17,908 8890 1560 63.1% 31.3% 5.5% 66.6% 33.4%
60–69 54,276 31,099 20,213 2964 57.3% 37.2% 5.5% 60.1% 39.9%
70–79 58,448 29,444 24,526 4478 50.4% 42.0% 7.7% 53.6% 46.4%
80–89 37,429 15,612 15,676 6141 41.7% 41.9% 16.4% 47.6% 52.4%
90–99 7317 2234 2645 2438 30.5% 36.1% 33.3% 41.2% 58.8%
Income deprivation quintile
1—least deprived 43,401 24,636 14,670 4095 56.8% 33.8% 9.4% 61.4% 38.6%
2 44,946 24,884 15,953 4109 55.4% 35.5% 9.1% 59.6% 40.4%
3 41,661 22,329 15,516 3816 53.6% 37.2% 9.2% 57.4% 42.6%
4 37,685 19,061 15,074 3550 50.6% 40.0% 9.4% 54.4% 45.6%
5—most deprived 34,308 16,499 14,784 3025 48.1% 43.1% 8.8% 51.4% 48.6%
Screening status
No or not applicable 186,007 93,520 74,315 18,172 50.3% 40.0% 9.8% 54.4% 45.6%
Yes 15,994 13,889 1682 423 86.8% 10.5% 2.6% 89.2% 10.8%
aAdditional morphology groups not shown due to small numbers: Breast: other specified carcinoma and specified not carcinoma. Endometrial: sarcoma and
unspecified/other. Ovarian: endometrioid, clear cell, carcinosarcoma, serous low grade, carcinoma low grade, and germ cell.
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screening detection status flattened differences by age in stage at
diagnosis, particularly for breast cancer.
Sex and stage. Across the 6 cancer sites that can occur in either
sex, men were at higher risk of advanced stage at diagnosis for
melanoma, lung and renal cancer, compared with women; in
contrast, women had a higher risk of advanced stage at diagnosis
of bladder cancer (Fig. 3). There was no evidence for variation in
stage at diagnosis by sex for colon and rectal cancer, with or
without adjustment for screening detection status.
Deprivation group and stage. Increasing deprivation was asso-
ciated with higher risk of advanced stage, with some variability
by cancer (Fig. 4). For 7/10 sites (bladder, breast, colon, rectal,
melanoma, ovarian and prostate cancer), more deprived patients
were at higher risk of advanced stage at diagnosis. However, for
lung, renal and endometrial cancer there was no evidence for
differences in risk of advanced stage cancer between the
deprivation groups (p > 0.05). For breast, colon and rectal cancer,
additionally adjusting for screening detection status made little
difference to associations with deprivation group. Values of data
visualised in Figs. 1–4 are included Supplementary Information—
Table 1.
Population impact of removing deprivation and ‘older age’
inequalities in stage at diagnosis
For the studied cancers, removing socio-demographic inequal-

































































Age at diagnosis Sex Deprivation Cancer site
Fig. 1 Adjusted odds ratios for diagnosis at advanced stage—all patients with any cancer site in the analysis sample (‘Model 1’ results).













































35 55 75 95 35 55 75 95 35 55 75 95 35 55 75 95 35
Age at diagnosis
Case-mix adjustment
Sex, deprivation, morphology + screen detection
55 75 95
4
Breast Colon Rectal Endometrial
Lung
p = 0.025
Melanoma Ovarian Prostate Renal
Fig. 2 Adjusted odds ratios for diagnosis at advanced stage by age (30–99 years) from models stratified by cancer site (‘Model 2’ results).
Unless otherwise reported, p < 0.001.
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proportion of all incident cases diagnosed at advanced stage by
4.1%, or approximately 8,300 patients each year in England
(Fig. 5 and Table 2—columns F and G). This would translate to
61.3% of patients with the 10 studied cancers being diagnosed
at stage I/II, from the observed 57.2% (Table 3). Considering the
absolute ‘distance’ to the aimed for 75% of all patients being
diagnosed in stage I/II by 2028, such potential elimination would
reduce the current ‘gap’ of 17.8% (75–57.2%) to 13.7%. And in
relative terms, potential elimination would help cover 23.1% of
the overall ‘distance to target’.
In Table 2 (top, columns F and G), it can also be seen that
potential elimination of inequalities in older age would decrease
the proportion of all incident cases diagnosed in advanced stage
by 2.1% (or around 4200 cases), whereas the corresponding
figures for potential elimination of deprivation inequalities are
1.2% (or around 2300 cases) and for potential elimination of sex
inequalities 0.8% (or around 1700 cases).
Considering the impact of potential elimination of socio-
demographic inequalities in stage at diagnosis by cancer site,
the largest absolute percentage increase in stage I/II was observed
for prostate (9.1%) and the lowest for breast cancer (2.1%).
Focussing on the two cancer sites with the greatest percentage of
advanced stage cases (Table 1), for lung cancer removing socio-
demographic inequalities would increase the percentage of cases
diagnosed in stage I/II from 26% currently to 28%, while for
ovarian cancer the respective percentage would increase from
28% currently to 33% (Table 3).
Within each specific cancer site, the relative the contribution of
older age, deprivation and sex varied considerably. For example,
for rectal cancer, elimination of deprivation inequalities alone
would account for most of the potential reduction, compared to
the contribution of eliminating age or sex inequalities. In contrast,
for lung cancer potential elimination of sex inequalities would be
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Fig. 3 Adjusted odds ratios for diagnosis at advanced stage by sex from models stratified by cancer site (‘Model 2’ results). Where not
































Age, sex, morphology + screen detection
Lung Melanoma Ovarian Prostate Renal
p = 0.024 p = 0.151 p = 0.394
p = 0.600p = 0.002
p = 0.013
Bladder Breast Colon Rectal Endometrial
Fig. 4 Adjusted odds ratios for diagnosis at advanced stage by income deprivation from models stratified by cancer site (‘Model 2’
results). Deprivation group 1 is the least deprived group. Unless otherwise reported, p < 0.001.
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Fig. 5 are included Supplementary Information—Table 2. We also
highlight the relative impact of potential elimination of inequal-
ities in relation to reduction in advanced stage cases as a
percentage of advanced stage diagnoses (Table 2—column H and
Table 3, last column).
Sensitivity analysis. Complete case analysis provided smaller
estimates of the excess risk of advanced stage cancer associated
with older age, sex and deprivation (Supplementary Information—
Figs. 1–3). In complete case analysis, alternative definitions of
advanced stage categories gave similar results for sex and
deprivation but different associations with age at diagnosis and
cancer site (Supplementary Information—Figs. 4–6).
DISCUSSION
Summary
We provide comprehensive evidence regarding socio-
demographic disparities in stage at diagnosis of ten common
cancers in a large European country population. Such associations
tend to be present, but their strength and direction varies
substantially by cancer site. Potential elimination of older age,
deprivation and sex inequalities in stage at diagnosis would
increase the percentage of patients diagnosed at stage I/II but the
increase would fall short of the ‘75% of cases diagnosed in stage I/
II’ target, though in proportional terms contributing nearly a
quarter of the total improvement needed to attain it.
Comparisons with prior literature
The findings substantially update and expand previous work
limited to a single English region (East of England) and relating
to an earlier study era (2006–2010).18 The larger (nationwide)
sample size of the present study has improved estimate
precision such that there is additional evidence of increasing
risk of advanced stage at diagnosis in older age for ovarian,
renal and lung cancer. Although we would not expect the
findings to be necessarily concordant with those from other
country populations, in general they are in keeping with
literature documenting the presence of a variable degree of
socio-demographic variation in stage at diagnosis for few
common cancers.10–16 However, compared with most previous
studies, we consider a larger number of common and rarer
cancers together, take into account screening detection status
and tumour morphology and estimate the population impact of
inequalities in stage at diagnosis. Across our analysis sample,
cancer site was associated with the largest amount of variation
in stage at diagnosis, which would support accounting for
cancer site case-mix in summary indicators of cancer stage
at diagnosis for geographically defined populations. Regarding
lung cancer in particular, we did not observe an association
between stage at diagnosis and deprivation; this is consistent
with other evidence and a meta-analysis of the global literature
on socioeconomic status and stage at diagnosis of lung
cancer.22–24
Strengths and limitations
A strength of our study is that we were able to adjust for screening
detection status, although this adjustment would not take into
account any indirect impact of screening on non-screening
detected cases. We found that adjustment for screening detection
status mediates associations with older age substantially (as can
be expected, as screening is targeted to specific age groups) but
has a relatively limited impact on differences in stage at diagnosis
by deprivation. A further strength is that we have adjusted
for tumour morphology differences. We could not adjust for use
of prostate-specific antigen (PSA) and some of the socio-
demographic variation in advanced stage at diagnosis of prostate
cancer may reflect greater use of PSA testing in the least deprived
groups.25 As our study was motivated by the public health target
for attaining earlier stage diagnosis for 75% of cancer patients by
2028, we did not consider the translation of differences in stage at
diagnosis into differences in life expectancy and number of years
lost due to inequalities. Eliminating differences in stage at
diagnosis between different age groups and cancer sites will
translate to variable impact in life years gained (depending on the
age and cancer site case-mix of the cancers that will be diagnosed
at an earlier stage). These questions should be addressed by
future research.
There were inconsistent differences in stage at diagnosis by
sex, with women being at greater risk of advanced stage than
men for bladder cancer and at lower risk for lung, melanoma and
renal cancer, with minimal variation for colon and rectal cancer.
These heterogeneous patterns of sex differences in stage at
diagnosis point to variable, cancer site-specific aetiologies. For
example, prior research indicates that lung tumours tend to grow
faster in men than women—consistent with the pattern we
observed.26 Social factors may contribute to sex differences in
stage at diagnosis for melanoma, such as differences between
men and women in bodily awareness and help-seeking
behaviour. Lastly, healthcare-related factors such as prolonged
0%












Fig. 5 Estimated impact of removing ‘older age’ (among individuals ≥65 years), sex and income deprivation inequalities. Impact is shown
as the reduction in the number of tumours diagnosed in stage III/IV as a percentage of total diagnoses of each cancer site, and of all sites
combined.
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Table 2. Estimated impact of removing ‘older age’, sex and income deprivation inequalities, based on models adjusting for morphology and
screening where appropriate.
















All combined Observed 202,001 86,435 (82,628, 90,242)
'Older age’
disparities
82,260 (78,468, 86,052) 4175 2.1% 5.1%
Sex disparities 84,720 (80,914, 8855) 1715 0.8% 2.0%
Deprivation
disparities
84,152 (80,464, 87,841) 2283 1.2% 2.7%
All 3 combined 78,148 (74,487, 81,808) 8287 4.1% 10.6%
Colon Observed 23,452 13,267 (12,778, 13,756)
'Older age’
disparities
13,193 (12,705, 13,682) 74 0.3% 0.6%
Sex disparities 13,169 (12,680, 13,658) 98 0.4% 0.7%
Deprivation
disparities
12,938 (12,457, 13,419) 329 1.4% 2.5%
All 3 combined 12,764 (12,287, 13,241) 503 2.1% 3.9%
Rectal Observed 11,279 6542 (6202, 6882)
'Older age’
disparities
6527 (6191, 6863) 15 0.1% 0.2%
Sex disparities 6441 (6088, 6794) 101 0.9% 1.6%
Deprivation
disparities
6298 (5957, 6640) 244 2.2% 3.9%
All 3 combined 6181 (5830, 6531) 361 3.2% 5.8%
Lung Observed 38,086 28,256 (27,639, 28,873)
'Older age’
disparities
28,243 (27,629, 28,856) 13 0.0% 0.0%
Sex disparities 27,455 (26,805, 28,106) 801 2.1% 2.9%
Deprivation
disparities
28,248 (27,622, 28,874) 8 0.0% 0.0%
All 3 combined 27,433 (27,777, 28,089) 823 2.2% 3.0%
Melanoma Observed 12,970 1232 (1020, 1444)
'Older age’
disparities
1086 (890, 1283) 146 1.1% 13.4%
Sex disparities 1044 (855, 1232) 188 1.5% 18.0%
Deprivation
disparities
1119 (934, 1304) 113 0.9% 10.1%
All 3 combined 830 (680, 981) 402 3.1% 48.4%
Breast Observed 45,432 7136 (6577, 7695)
'Older age’
disparities
6871 (6314, 7429) 265 0.6% 3.9%
Deprivation
disparities
6433 (5919, 6946) 703 1.5% 10.9%
Both combined 6186 (5677, 6695) 950 2.1% 15.4%
Endometrial Observed 7316 1560 (1322, 1798)
'Older age’
disparities
1353 (1127, 1580) 207 2.8% 15.3%
Deprivation
disparities
1480 (1251, 1709) 80 1.1% 5.4%
Both combined 1278 (1061, 1495) 282 3.9% 22.1%
Ovarian Observed 5002 3602 (3392, 3812)
‘Older age’
disparities
3462 (3233, 3691) 140 2.8% 4.0%
Deprivation
disparities
3497 (3283, 3712) 104 2.1% 3.0%
Both combined 3347 (3113, 3581) 254 5.1% 7.6%
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intervals from presentation to referral in women may be at least
partly responsible for sex differences in stage at diagnosis of
bladder cancer.27,28
Stage data were highly complete overall, though, as is the case
for studies using nationwide population-based registry data, a
small minority of patients had missing stage information.
Concordant with best practice in this field, we used multiple
imputation to assign stage (using information from several
auxiliary variables included in the imputation but not the analysis
model), which mitigates this limitation.29–32 Complete case
analysis provided very similar findings.
Consistent with the public policy target that our research was
motivated by, we have not considered the potential impact of
elimination of variation in stage at diagnosis onto inequalities in
survival or life years gained by the patient group.33
Implications
The findings suggest the presence of common reasons for
differences in stage at diagnosis among older people and
between deprivation groups, across cancer sites. These may
include psychosocial factors acting as barriers to prompt
presentation/help-seeking.34,35 Targeted public health awareness
campaigns focussing on specific cancers and/or population
groups at higher risk of advanced stage disease would therefore
be justified given the findings, particularly for cancer sites with a
symptom signature dominated by symptoms with relatively high
positive predictive value, for example for melanoma (melanotic
skin lesion), breast (breast lump), bladder (haematuria), rectal
(rectal bleeding) and endometrial cancer (post-menopausal
bleeding).36 The majority of cancer patients with these symptoms
have non-advanced stage disease.37
Although deprivation is not associated with variation in stage at
diagnosis of lung cancer, given the very strong socioeconomic
gradients in incidence, preventive efforts (e.g. through smoking
cessation policies) are strongly justified. Increasing participation in
bowel cancer screening can also help to achieve a favourable
earlier stage shift.
In spite of clear socio-demographic inequalities in stage at
diagnosis, their potential reduction would contribute substantially
to achieving earlier stage diagnosis targets but will only help
‘bridge’ around a quarter of ‘distance-to-target’. Therefore, public
health strategies to improve the distribution of stage at diagnosis
of cancer should additionally focus on the whole population,
rather than socio-demographic groups at higher risk. Novel
diagnostic tests and strategies are additionally needed to enable
earlier detection of cancer in both asymptomatic and sympto-
matic patients of any socio-demographic group.38
Table 2. continued
















Prostate Observed 40,959 18,572 (18,013, 19,131)
'Older age’
disparities
15,449 (14,888, 16,011) 3123 7.6% 20.2%
Deprivation
disparities
17,981 (17,458, 18,504) 591 1.4% 3.3%
Both combined 14,854 (14,334, 15,375) 3718 9.1% 25.0%
Renal Observed 8933 3845 (3526, 4164)
'Older age’
disparities
3652 (3331, 3973) 193 2.2% 5.3%
Sex disparities 3501 (3180, 3823) 344 3.9% 9.8%
Deprivation
disparities
3829 (3511, 4147) 16 0.2% 0.4%
All 3 combined 3295 (2971, 3619) 550 6.2% 16.7%
Bladder Observed 8572 2423 (2169, 2677)
'Older age’
disparities
2343 (2089, 2598) 80 0.9% 3.4%
Sex disparities 2239 (2002, 2477) 184 2.1% 8.2%
Deprivation
disparities
2227 (1986, 2468) 196 2.3% 8.8%
All 3 combined 1979 (1757, 2201) 444 5.2% 22.4%
Table 3. Percentage improvement in percentage of patients
diagnosed in stage I/II by cancer site.
Cancer site % stage I/
II as
observed

















All combined 57.2% 61.3% 4.1% 10.6%
Prostate 54.7% 63.7% 9.1% 25.0%
Renal 56.8% 63.1% 6.2% 16.7%
Bladder 71.5% 76.9% 5.2% 22.4%
Ovarian 28.0% 33.1% 5.1% 7.6%
Endometrial 78.8% 82.5% 3.9% 22.1%
Rectal 42.1% 45.2% 3.2% 5.8%
Melanoma 90.6% 93.6% 3.1% 48.4%
Lung 25.8% 28.0% 2.2% 3.0%
Colon 43.3% 45.6% 2.1% 3.9%
Breast 84.2% 86.4% 2.1% 15.4%
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